Your Account
“Hopeful times” anticipated by leading MS advocate upon approval of MS treatment
28.04.2013
The European Commission has granted marketing authorization for Aubagio 14 mg (teriflunomide), an oral therapy recommended for the treatment of…
The Written Declaration bid for neurodegenerative diseases: a useful experience
28.03.2013
The bid for a Written Declaration for neurodegenerative diseases (NDDs) in the workplace managed to gather 161 signatures from Members…
